Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
about
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@en
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@nl
type
label
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@en
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@nl
prefLabel
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@en
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@nl
P2093
P2860
P1476
Twelve weeks of ombitasvir/par ...... rom a real-world cohort study.
@en
P2093
Ana De Lorenzo-Pinto
Carmen-Guadalupe Rodriguez-Gonzalez
Esther Chamorro-de-Vega
GRUviC Study Group
Irene Iglesias-Peinado
Maria Sanjurjo Saez
Vicente Escudero-Vilaplana
P2860
P304
P356
10.1080/14740338.2018.1424829
P407
P577
2018-01-11T00:00:00Z